Just two breast cancer news updates today.
Another Phase II study of the NeuVax vaccine for HER2 positive patients
Yesterday, there was a Boston Business Journal story on positive Phase II results for the NeuVax vaccine for HER2 positive breast cancer patients not eligible for Herceptin. Today, a Business Wire press release revealed positive results of another Phase II NeuVax study. In today's study, none of the patients who received Herceptin (trastuzumab) plus NeuVax experienced a recurrence, while 12.5% of those who received Herceptin alone did. At LATESTBreastCancer.com, we'll continue to keep an eye on this one. Any news or research will be posted on the NeuVax page of our website.
Paraplatin adds no benefit or toxicity to chemo combo for basal-like cancer
Internal Medicine News reported on a study which found that adding Paraplatin (carboplatin) to standard chemotherapy for basal-like (similar to triple-negative) breast cancer added no benefit or toxicity. Paraplatin is a DNA-damaging agent. The authors speculate that the lack of benefit may have been due to the fact that patients were also exposed to Ellence (epirubicin), another DNA-damaging agent.
Please check back tomorrow for more breast cancer news updates from LATESTBreastCancer.com.